Search - tctmd.com

Displaying 281 - 300 of 428

Sort: Relevancy | Date

News Daily News

Omega-3 PUFAs Offset Adverse CV Effects of Air Pollution in Small, Chinese Study

Michael O'Riordan

April 24, 2019

News Daily News

Initiative Helps Low-Resource Chinese Hospitals Provide Better ACS Care

L.A. McKeown

April 17, 2019

News Daily News

Less Not Always More When Medicating Frail, Elderly Acute MI Patients

L.A. McKeown

April 16, 2019

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Daily News

No Free Brunch? Eggs Once Again Feel the Scramble in New, Large Observational Study

Caitlin E. Cox

March 22, 2019

News Conference News ACC 2019

CODIACS-QoL: Depression Screening in ACS Patients Fails to Boost Quality of Life

L.A. McKeown

March 16, 2019

News Daily News

Rising Number of CV-Related Maternal Deaths Spurs Need for #CardioObstetrics

Caitlin E. Cox

February 27, 2019

News Daily News

Many CVD Risk Factors Remain Uncontrolled in Men and Women, but Emphasis Differs

Lucy Hicks

February 21, 2019

News Daily News

One in Two Americans Have Cardiovascular Disease: AHA Stats

Michael O'Riordan

February 04, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Daily News

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Michael O'Riordan

January 29, 2019

News Daily News

AAA Rupture Rate in England Supports Current Thresholds for Surveillance, Intervention—With Some Caveats

Shelley Wood

January 21, 2019

News Daily News

Dose-Response Benefits for Fiber Intake Seen Across Wide Swath of Acquired Diseases

Shelley Wood

January 15, 2019

News Daily News

AHA Scientific Statement: Get PAD Patients Moving to Improve Symptoms and QoL

L.A. McKeown

January 03, 2019

News Daily News

Data Hint at Unintended Consequences of Hospital Readmissions Reduction Program

L.A. McKeown

December 21, 2018

News Conference News WCC 2018

Rising CVD Threatens Middle East and North Africa

Todd Neale

December 13, 2018

News Daily News

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Michael O'Riordan

December 10, 2018

News Conference News WCC 2018

E-Cigarettes: Plausible Heart Risks Flagged in New Review

Todd Neale

December 10, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

Advertisement

Omega-3 PUFAs Offset Adverse CV Effects of Air Pollution in Small, Chinese Study

Initiative Helps Low-Resource Chinese Hospitals Provide Better ACS Care

Less Not Always More When Medicating Frail, Elderly Acute MI Patients

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

No Free Brunch? Eggs Once Again Feel the Scramble in New, Large Observational Study

CODIACS-QoL: Depression Screening in ACS Patients Fails to Boost Quality of Life

Rising Number of CV-Related Maternal Deaths Spurs Need for #CardioObstetrics

Many CVD Risk Factors Remain Uncontrolled in Men and Women, but Emphasis Differs

One in Two Americans Have Cardiovascular Disease: AHA Stats

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

AAA Rupture Rate in England Supports Current Thresholds for Surveillance, Intervention—With Some Caveats

Dose-Response Benefits for Fiber Intake Seen Across Wide Swath of Acquired Diseases

AHA Scientific Statement: Get PAD Patients Moving to Improve Symptoms and QoL

Data Hint at Unintended Consequences of Hospital Readmissions Reduction Program

Rising CVD Threatens Middle East and North Africa

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

E-Cigarettes: Plausible Heart Risks Flagged in New Review

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content